Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis | Zendy

Satoshi Kitai | Zendy; Masatoshi Kudo | Zendy; Naoshi Nishida | Zendy; Namiki Izumi | Zendy; Michiie Sakamoto | Zendy; Yutaka Matsuyama | Zendy; Takafumi Ichida | Zendy; Osamu Nakashima | Zendy; Osamu Matsui | Zendy; Yonson Ku | Zendy; Norihiro Kokudo | Zendy; Masatoshi Makuuchi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis

Author(s) -

Satoshi Kitai,

Masatoshi Kudo,

Naoshi Nishida,

Namiki Izumi,

Michiie Sakamoto,

Yutaka Matsuyama,

Takafumi Ichida,

Osamu Nakashima,

Osamu Matsui,

Yonson Ku,

Norihiro Kokudo,

Masatoshi Makuuchi

Publication year - 2016

Publication title -

liver cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.916

H-Index - 34

eISSN - 2235-1795

pISSN - 1664-5553

DOI - 10.1159/000367765

Subject(s) - medicine , hepatocellular carcinoma , propensity score matching , hazard ratio , gastroenterology , liver transplantation , cirrhosis , confidence interval , milan criteria , liver cancer , transplantation

Hepatocellular carcinoma (HCC) with decompensated liver cirrhosis (LC) is a life-threatening condition, which is amenable to liver transplantation (LT) as the standard first-line treatment. However, the application of LT can be limited due to a shortage of donor livers. This study aimed to clarify the effect of non-surgical therapy on the survival of patients with HCC and decompensated LC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research